Q2 2017 13F Holders as of 6/30/2017
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
108M
-
Number of holders
-
80
-
Total 13F shares, excl. options
-
16.8M
-
Shares change
-
+62.3K
-
Total reported value, excl. options
-
$269M
-
Value change
-
+$2.72M
-
Put/Call ratio
-
1.19
-
Number of buys
-
54
-
Number of sells
-
-22
-
Price
-
$16.00
Significant Holders of Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NTLA) as of Q2 2017
95 filings reported holding NTLA - Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q2 2017.
Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NTLA) has 80 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 16.8M shares
of 108M outstanding shares and own 15.58% of the company stock.
Largest 10 shareholders include Atlas Venture Associates IX, LLC (3.73M shares), FMR LLC (3.23M shares), ORBIMED ADVISORS LLC (2.66M shares), BlackRock Inc. (1.68M shares), BAKER BROS. ADVISORS LP (1.06M shares), VANGUARD GROUP INC (997K shares), Temasek Holdings (Private) Ltd (791K shares), GRANAHAN INVESTMENT MANAGEMENT INC/MA (267K shares), Artal Group S.A. (250K shares), and MORGAN STANLEY (245K shares).
This table shows the top 80 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.